title: Optimum conditions for detecting hepatic micronuclei caused by numerical chromosome aberration inducers in mice.
abstract: To ascertain an optimum condition for detecting micronuclei in the liver caused by numerical aberration inducers, either carbendazim (125-1000mg/kg, p.o.), colchicine (0.375-1.5mg/kg, i.v.), cytochalasin B (2.5-20mg/kg, i.v.), diazepam (3.13-25mg/kg, i.v.), noscapine (7.8-62.5mg/kg, i.v.), paclitaxel (1-100mg/kg, i.v.) or trichlorfon (18.75-150mg/kg, i.v.) was administered once to male Slc:ddY mice 1 day before or after partial hepatectomy (PH, Day 1). Five days after PH (on Day 6), hepatic micronuclei were determined in conjunction with classifications of the main nuclei and relative liver weights as a proliferative indicator or a dysfunction marker of cell division. Additionally, hepatocyte proliferation index (HPI) was calculated by using mono-, bi- and multinucleated cell counts. Treatment of mice with six compounds, except for colchicine, after PH showed higher incidence of micronucleated hepatocytes (MNH) than that before PH, and also increases in binucleated and multinucleated cells. Especially for carbendazim, diazepam, noscapine and trichlorfon, the dosing after PH was essential for the detecting numerical aberration. Colchicine evidently increased HPI and decreased relative liver weights without MNH induction on Day 6. On Day 8 when HPI and relative liver weights almost returned to the basal range, a significant increase in MNH was noted. This implied that the strong inhibition of colchicine on hepatocyte proliferation may obstruct the induction of MNH on Day 6. In conclusion, to detect the potential numerical aberration, exposure of mice to test chemicals should be performed 1 day after PH, during which enhanced proliferation of hepatocytes was seen, and it would be better to analyze the liver specimens on Day 6 or more post-PH.
authors.affiliation: Drug Safety Research Laboratory, R & D Division, Daiichi Pharmaceutical Co., Ltd. 16-13, Kita-Kasai 1-Chome, Edogawa-ku, Tokyo 134-8630, Japan. igaraoeh@daiichipharm.co.jp
authors.forename: Miyuki
authors.initials: M
authors.lastname: Igarashi
authors.forename: Mayumi
authors.initials: M
authors.lastname: Setoguchi
authors.forename: Sanae
authors.initials: S
authors.lastname: Takada
authors.forename: Satoru
authors.initials: S
authors.lastname: Itoh
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Furuhama
mesh_terms: D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D002869:Chromosome Aberrations / Q000139:chemically induced*; D003078:Colchicine / Q000008:administration & dosage / Q000633:toxicity; D006498:Hepatectomy; D022781:Hepatocytes / Q000000981:diagnostic imaging; D008099:Liver / Q000648:ultrastructure*; D008115:Liver Regeneration / Q000187:drug effects; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D048629:Micronuclei, Chromosome-Defective / Q000139:chemically induced*; D015162:Micronucleus Tests / Q000379:methods*; D009929:Organ Size / Q000187:drug effects; D013997:Time Factors; D014463:Ultrasonography
chemical_list: D003078:Colchicine